|
Jim Barrett joined NEA in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. Present board memberships include CoGenesys, GlycoMimetics, Inhibitex, Inc. (NASDAQ: INHX), Iomai Corporation, Nucleonics, Inc., Peptimmune, Inc., Pharmion Corporation (NASDAQ: PHRM), Ruxton Pharmaceuticals, Inc., Sensors for Medicine and Science, Supernus Pharmaceuticals, Targacept, and he formerly served on the board of MedImmune, Inc., which was recently purchased by AstraZeneca. Prior to NEA, Mr. Barrett served as Founder/Chairman/CEO of Sensors for Medicine and Science (1997 - 2001) where he remains Chairman. Prior to that, he was Chairman/CEO of Genetic Therapy (1987 - 1995), President/CEO of Life Technologies (1985 - 1987), and President/CEO of Bethesda Research Labs (1982 - 1983). Before 1982, he worked in various divisions of SmithKline. Mr. Barrett has worked with NEA since 1982 when he was recruited to run Bethesda Research Laboratories, which merged with Life Technologies. NEA then backed him at Genetic Therapy and later at Sensors for Medicine and Science. Mr. Barrett received a PhD in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College. | 